Shoring up medical security
Company eyeing growth prospects in the region amidst international tie-ups
NOT many in the pharmaceutical industry are looking at biosimilar medicine, but it is an area that Inno Bio Ventures Sdn Bhd (IBV) chairman Tan Sri Abdul Rahman Mamat intends to build the company on.
“One thing about the biosimilar sector is that the developmental costs are very high and the private sector is not willing to put money into the development cost which would cover research and development (R&D),” says Rahman.
...
The content is a snapshot from Publisher. Refer to the original content for accurate info. Contact us for any changes.
Related Stocks
INNO | 1.470 |
Comments